Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.64
MKGAY's Cash to Debt is ranked higher than
61% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MKGAY: 0.64 )
MKGAY' s 10-Year Cash to Debt Range
Min: 0.45   Max: No Debt
Current: 0.64

Equity to Asset 0.52
MKGAY's Equity to Asset is ranked higher than
62% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MKGAY: 0.52 )
MKGAY' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.57
Current: 0.52

0.46
0.57
F-Score: 5
Z-Score: 2.04
M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 15.12
MKGAY's Operating margin (%) is ranked higher than
84% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. MKGAY: 15.12 )
MKGAY' s 10-Year Operating margin (%) Range
Min: 2.84   Max: 19.54
Current: 15.12

2.84
19.54
Net-margin (%) 10.60
MKGAY's Net-margin (%) is ranked higher than
81% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. MKGAY: 10.60 )
MKGAY' s 10-Year Net-margin (%) Range
Min: 2.91   Max: 49.88
Current: 10.6

2.91
49.88
ROE (%) 21.11
MKGAY's ROE (%) is ranked higher than
94% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. MKGAY: 21.11 )
MKGAY' s 10-Year ROE (%) Range
Min: 3.95   Max: 56.59
Current: 21.11

3.95
56.59
ROA (%) 11.03
MKGAY's ROA (%) is ranked higher than
92% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. MKGAY: 11.03 )
MKGAY' s 10-Year ROA (%) Range
Min: 2.33   Max: 30.58
Current: 11.03

2.33
30.58
ROC (Joel Greenblatt) (%) 96.63
MKGAY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. MKGAY: 96.63 )
MKGAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.06   Max: 53.26
Current: 96.63

8.06
53.26
Revenue Growth (%) 6.10
MKGAY's Revenue Growth (%) is ranked higher than
73% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MKGAY: 6.10 )
MKGAY' s 10-Year Revenue Growth (%) Range
Min: -11.6   Max: 15.8
Current: 6.1

-11.6
15.8
EBITDA Growth (%) 9.10
MKGAY's EBITDA Growth (%) is ranked higher than
76% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. MKGAY: 9.10 )
MKGAY' s 10-Year EBITDA Growth (%) Range
Min: -11.4   Max: 27.9
Current: 9.1

-11.4
27.9
EPS Growth (%) 24.10
MKGAY's EPS Growth (%) is ranked higher than
86% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MKGAY: 24.10 )
MKGAY' s 10-Year EPS Growth (%) Range
Min: -25.5   Max: 51.8
Current: 24.1

-25.5
51.8
» MKGAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MKGAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.00
MKGAY's P/E(ttm) is ranked higher than
95% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. MKGAY: 14.00 )
MKGAY' s 10-Year P/E(ttm) Range
Min: 10.2   Max: 261.35
Current: 14

10.2
261.35
P/B 0.84
MKGAY's P/B is ranked higher than
96% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. MKGAY: 0.84 )
MKGAY' s 10-Year P/B Range
Min: 0.35   Max: 0.88
Current: 0.84

0.35
0.88
P/S 1.49
MKGAY's P/S is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. MKGAY: 1.49 )
MKGAY' s 10-Year P/S Range
Min: 0.59   Max: 7.96
Current: 1.49

0.59
7.96
PFCF 23.00
MKGAY's PFCF is ranked higher than
91% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 23.00 )
MKGAY' s 10-Year PFCF Range
Min: 5.92   Max: 24.05
Current: 23

5.92
24.05
EV-to-EBIT 2.85
MKGAY's EV-to-EBIT is ranked higher than
99% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. MKGAY: 2.85 )
MKGAY' s 10-Year EV-to-EBIT Range
Min: 2.9   Max: 114.2
Current: 2.85

2.9
114.2
PEG 1.06
MKGAY's PEG is ranked higher than
95% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 1.06 )
MKGAY' s 10-Year PEG Range
Min: 0.23   Max: 0.42
Current: 1.06

0.23
0.42
Shiller P/E 30.90
MKGAY's Shiller P/E is ranked higher than
86% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. MKGAY: 30.90 )
MKGAY' s 10-Year Shiller P/E Range
Min: 25.77   Max: 43.06
Current: 30.9

25.77
43.06
Current Ratio 1.26
MKGAY's Current Ratio is ranked higher than
54% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. MKGAY: 1.26 )
MKGAY' s 10-Year Current Ratio Range
Min: 1.2   Max: 3.09
Current: 1.26

1.2
3.09
Quick Ratio 0.97
MKGAY's Quick Ratio is ranked higher than
56% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. MKGAY: 0.97 )
MKGAY' s 10-Year Quick Ratio Range
Min: 0.89   Max: 2.62
Current: 0.97

0.89
2.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.93
MKGAY's Dividend Yield is ranked lower than
64% of the 519 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MKGAY: 0.93 )
MKGAY' s 10-Year Dividend Yield Range
Min: 0.89   Max: 5.19
Current: 0.93

0.89
5.19
Dividend Payout 0.25
MKGAY's Dividend Payout is ranked higher than
86% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 0.25 )
MKGAY' s 10-Year Dividend Payout Range
Min: 0.86   Max: 5.77
Current: 0.25

0.86
5.77
Dividend growth (3y) 19.60
MKGAY's Dividend growth (3y) is ranked higher than
89% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MKGAY: 19.60 )
MKGAY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 19.6
Current: 19.6

0
19.6
Yield on cost (5-Year) 0.46
MKGAY's Yield on cost (5-Year) is ranked lower than
80% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. MKGAY: 0.46 )
MKGAY' s 10-Year Yield on cost (5-Year) Range
Min: 0.46   Max: 2.66
Current: 0.46

0.46
2.66

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 38.87
MKGAY's Price/Tangible Book is ranked higher than
54% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.32 vs. MKGAY: 38.87 )
MKGAY' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 37.07
Current: 38.87

1.45
37.07
Price/DCF (Projected) 1.47
MKGAY's Price/DCF (Projected) is ranked higher than
91% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. MKGAY: 1.47 )
MKGAY' s 10-Year Price/DCF (Projected) Range
Min: 0.33   Max: 1.4
Current: 1.47

0.33
1.4
Price/Median PS Value 0.91
MKGAY's Price/Median PS Value is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. MKGAY: 0.91 )
MKGAY' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 4.75
Current: 0.91

0.39
4.75
Price/Peter Lynch Fair Value 0.57
MKGAY's Price/Peter Lynch Fair Value is ranked higher than
99% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 0.57 )
MKGAY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44   Max: 0.54
Current: 0.57

0.44
0.54
Price/Graham Number 2.68
MKGAY's Price/Graham Number is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.17 vs. MKGAY: 2.68 )
MKGAY' s 10-Year Price/Graham Number Range
Min: 0.65   Max: 2.56
Current: 2.68

0.65
2.56
Earnings Yield (Greenblatt) 35.10
MKGAY's Earnings Yield (Greenblatt) is ranked higher than
99% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MKGAY: 35.10 )
MKGAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 34.9
Current: 35.1

0.9
34.9
Forward Rate of Return (Yacktman) 39.90
MKGAY's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. MKGAY: 39.90 )
MKGAY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7   Max: 51.7
Current: 39.9

7
51.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LSE:0NZZ, TKPYY, TEVA, AGN, FRX » details
Traded in other countries:MRK.Germany, 0O14.UK, MER.Switzerland,
Merck KGaA is a pharmaceutical and chemical company. It operates as a manufacturer of standard and specialty chemicals for the laboratory and industry. he Company researches drugs in the areas oncology and neurodegenerative as well as autoimmune and inflammatory diseases. The Company operate its businesses in four divisions: Merck Serono (prescription medicines), Consumer Health (over-the-counter pharmaceuticals), Performance Materials (high-tech chemicals) and Merck Millipore (products for pharmaceutical research and biotechnology).:. Within the Merck Serono division, the Company researches on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for flat screens and the pharmaceutical, food, cosmetics, packaging, and coatings.
» More Articles for MKGAY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Merck KGaA -- Moody's downgrades Merck KGaA's ratings to Baa1; negative outlook Dec 12 2014
Merck Issues Euro Hybrid Bond Amounting to € 1.5 billion Dec 08 2014
Sigma-Aldrich Shareholders Approve Merger With Merck Dec 05 2014
Merck Joins “Together for Sustainability” Network Dec 03 2014
Merck KGaA -- Moody's assigns (P)Baa3 to Merck KGaA's new hybrid notes Dec 01 2014
Merck Millipore Launches Kit for Analyzing NF?B Translocation by Imaging Flow Cytometry Nov 28 2014
Merck’s Consumer Health Division Sparks Debate on Future of OTC Sector Nov 28 2014
Merck Commissions Biomass Energy Plant in India Nov 25 2014
Merck KGaA, Darmstadt, Germany, Commissions Biomass Energy Plant in India Nov 25 2014
SAP SE -- Moody's: Focus of European M&A shifts to US companies Nov 17 2014
US, German drugmakers team up on cancer medicines Nov 17 2014
US, German drugmakers team up on cancer medicines Nov 17 2014
[video]European Stocks Follow Asia Lower as Japan Slips Into Recession Nov 17 2014
Merck KGaA, Darmstadt, Germany, Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to... Nov 17 2014
Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in... Nov 17 2014
[video]European Stocks Rise, Merck KGaA and Alstom Lead the Advance Nov 13 2014
Merck Holds “Displaying Futures” Symposium in Shanghai Nov 05 2014
Merck: Executive Board Member Oschmann Elected President of IFPMA Nov 04 2014
Merck KGaA: Executive Board Member Oschmann Elected President of IFPMA Nov 04 2014
Merck Millipore’s New SNAP i.d.® 2.0 System for Immunohistochemistry Minimizes Slide Handling Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK